CD163 and ovarian carcinoma: Clinical data were obtained from a publicly available ovarian cancer dataset by Tothill et al.[47] Our analysis revealed that the expression of CD163 and CD206 alone did not significantly impact overall survival (Figure S8C,D, Supporting Information).